Get the Stockscreener App
93.21
16.50%
13.20
After Hours:
95.00
1.79
+1.92%
Bright Minds Biosciences Inc stock is traded at $93.21, with a volume of 1.12M.
It is up +16.50% in the last 24 hours and up +15.79% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$80.01
Open:
$119.8
24h Volume:
1.12M
Relative Volume:
6.13
Market Cap:
$725.84M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-70.74
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+22.89%
1M Performance:
+15.79%
6M Performance:
+228.55%
1Y Performance:
+125.09%
1-Day Range:
$89.29
$123.75
1-Week Range:
$72.03
$123.75
52-Week Range:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
93.21 | 623.05M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Market movers: Bright Mind Biosciences, Sandisk, Under Armour… - Proactive Investors
Bright Minds Stock Surges 22% After Positive Phase 2 Topline Results - Nasdaq
Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00 - MarketBeat
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Benzinga
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 12-Month HighWhat's Next? - MarketBeat
Bright Mind Biosciences shares surge on positive epilepsy drug trial results - Proactive financial news
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why did DRUG stock rocket 51% today? - MSN
Market movers: Bright Mind Biosciences, Sandisk, Under Armour, OPT… - Proactive financial news
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Australia
Bright Minds posts mid-stage trial win for lead drug (DRUG) - Seeking Alpha
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) - The Manila Times
Bright Minds Biosciences stock climbs after positive Phase 2 trial results - Investing.com UK
DRUG: BMB-101 achieved robust seizure reduction and improved REM sleep in drug-resistant epilepsy - TradingView — Track All Markets
Bright Minds Biosciences Announces Positive Topline Results - GlobeNewswire
Experimental drug sharply cuts hard-to-treat seizures, boosts REM - Stock Titan
(DRUG) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Bright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE - Nasdaq
Bright Minds Biosciences Stock Pre-Market (+10%) : BMB-101 Phase 2 Topline Data Release - Trefis
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
New epilepsy medication from Bright Minds reduces seizures, boosting stock price on Tuesday - Bitget
Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures - TipRanks
Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6 - marketscreener.com
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday - Investing.com Australia
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - The Manila Times
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday By Investing.com - Investing.com South Africa
New trial results in drug-resistant seizures to be revealed Tuesday - Stock Titan
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.7%Time to Sell? - MarketBeat
Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - MarketBeat
Bright Minds Biosciences (DRUG) Expected to Announce Quarterly Earnings on Monday - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase – Time to Buy? - Defense World
How Bright Minds Biosciences Inc. stock performs in high volatility marketsDividend Stability Analysis & Superior Trading Ideas - bollywoodhelpline.com
Bright Minds Biosciences (DRUG) Projected to Post Earnings on Monday - MarketBeat
DRUG: R&D-driven net loss rose to $12.2M; $82.9M cash secures 12+ months' runway amid ongoing clinical trials - TradingView — Track All Markets
Will Bright Minds Biosciences Inc. stock reach Wall Street targetsLayoff News & Low Drawdown Trading Strategies - Улправда
How institutional buying supports Bright Minds Biosciences Inc. stock2025 Market Sentiment & Stock Market Timing Techniques - Улправда
Why Bright Minds Biosciences Inc. stock is popular among millennials2025 Market Overview & Weekly High Return Stock Forecasts - Улправда
TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 By Investing.com - Investing.com Canada
Will Bright Minds Biosciences Inc. stock deliver shareholder valueMarket Performance Summary & Risk Controlled Stock Pick Alerts - Улправда
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 5.4%Here's What Happened - MarketBeat
Bullish Divergence Spotted in Tulsyan NEC Limited MomentumDividend Yield Trends & Fast Growing Investment Plans - earlytimes.in
Bright Minds Biosciences Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Tools to Monitor Market Corrections - earlytimes.in
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):